AVALO THERAPEUTICS, INC. (AVTX)

Import this data to Google Sheets with:

=jivedata("AVTX","financials")

Full statements spill as a table. For one cell: =jivedata("AVTX","Revenue") or =jivedata("AVTX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

AVALO THERAPEUTICS, INC.

AVTX • CIK 0001534120

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-27,351	$-68,512	$-72,925	$-91,360
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-31,530	$-35,015	$-78,094	$-100,163
Income Tax Expense (Benefit)	$14	$114	$165	$170
Net Income (Loss) Attributable to Parent	$-31,544	$-35,129	$-78,259	$-100,333
Weighted Average Number of Shares Outstanding, Basic	277,727	4,426,149	13,404,830	34,651,018
Weighted Average Number of Shares Outstanding, Diluted	277,727	7,496,389	13,404,830	34,651,018
Revenue from Contract with Customer, Excluding Assessed Tax	$1,924	$441	$59	$59
Research and Development Expense (Excluding Acquired in Process Cost)	$13,784	$24,437	$50,084	$64,355
General and Administrative Expense	—	$17,241	$22,900	$27,064
Costs and Expenses	$29,275	$68,953	$72,984	$91,419
Interest Income (Expense), Nonoperating, Net	$-3,417	$3,317	$4,351	$5,666
Fair Value Adjustment of Warrants	—	$-121,611	$0	$0
Nonoperating Income (Expense)	$-4,179	$33,497	$-5,169	$-8,803
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	—	—	$-78,191	$-100,882
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	—	—	$68	$-549

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Goodwill	$10,502	$10,502	$10,502	$10,502
Restricted Cash and Cash Equivalents, Noncurrent	$131	$131	$210	$183
Assets	$20,993	$150,732	$116,458	$490,783
Accrued Royalties	$2,000	$2,000	$2,000	$2,000
Deferred Income Tax Liabilities, Net	$155	$270	$434	$463
Derivative Liability, Noncurrent	$5,550	$8,120	$18,000	$18,530
Other Liabilities, Noncurrent	$1,366	$350	$35	$0
Liabilities	$13,689	$17,700	$33,409	$42,123
Cash and Cash Equivalents, at Carrying Value	$7,415	$134,546	$15,858	$85,382
Short-term Investments	—	—	$82,478	$314,894
Prepaid Expense and Other Assets, Current	$843	$3,714	$6,913	$7,607
Restricted Cash and Cash Equivalents, Current	$1	$19	$37	$49
Assets, Current	$8,395	$138,890	$105,286	$407,932
Accounts Payable, Current	$446	$283	$137	$3,347
Accrued Liabilities and Other Liabilities	$4,172	$6,317	$12,803	$17,783
Derivative Liability, Current	—	$360	$0	$0
Liabilities, Current	$4,618	$6,960	$12,940	$21,130
Temporary Equity, Carrying Amount, Attributable to Parent	—	$0	$0	$0
Common Stock, Value, Issued	$1	$10	$18	$53
Additional Paid in Capital	$342,437	$503,285	$531,485	$953,700
Accumulated Other Comprehensive Income (Loss), Net of Tax	—	—	$68	$-583
Retained Earnings (Accumulated Deficit)	$-335,134	$-370,263	$-448,522	$-504,510
Stockholders' Equity Attributable to Parent	$7,304	$133,032	$83,049	$448,660
Temporary Equity, Shares Authorized	—	5,000,000	—	5,000,000
Temporary Equity, Shares Outstanding	—	2	2	0
Common Stock, Shares Authorized	200,000,000	200,000,000	200,000,000	200,000,000
Common Stock, Shares, Issued	801,746	10,471,934	18,512,757	52,900,692
Preferred Stock, Shares Authorized	5,000,000	5,000,000	5,000,000	5,000,000
Operating Lease, Right-of-Use Asset	$1,329	$741	$336	$198
Operating Lease, Liability, Current	$537	$568	$392	$242
Operating Lease, Liability	$1,903	$918	$427	$242

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-31,544	$-35,129	$-78,259	$-100,333
Net Cash Provided by (Used in) Operating Activities	$-30,680	$-49,056	$-51,458	$-68,290
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-5,771	$127,149	$-118,591	$43,094
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$7,547	$134,696	$16,105	$-83,816
Cash and Cash Equivalents, at Carrying Value	$7,415	$134,546	$15,858	$-84,200
Restricted Cash and Cash Equivalents, Current	$1	$19	$37	$122
Restricted Cash and Cash Equivalents, Noncurrent	$131	$131	$210	$262
Depreciation, Depletion and Amortization	$158	$169	$344	$109
Payments to Acquire Short-term Investments	—	—	$113,720	$396,661
Share-based Payment Arrangement, Noncash Expense	$3,477	$5,852	$13,621	$16,542
Proceeds from Sale and Maturity of Marketable Securities	—	—	$32,000	$32,000
Accretion (Amortization) of Discounts and Premiums, Investments	—	—	$690	$1,068
Cash Acquired from Acquisition	—	$356	$0	$0
Net Cash Provided by (Used in) Investing Activities	$-133	$356	$-81,720	$-315,280
Fair Value Adjustment of Warrants	—	$-121,611	$0	$0
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	—	$-12,500	$0	$6,574
Gain (Loss) on Termination of Lease	—	$309	$0	$0
Deferred Income Tax Expense (Benefit)	$14	$114	$165	$170
Proceeds from Issuance of Common Stock	$46,200	$0	$14,762	$14,762
Payments of Stock Issuance Costs	—	—	$462	$462
Proceeds from Stock Options Exercised	—	—	$774	$8,183
Proceeds from Stock Plans	$67	$68	$23	$49
Payment, Tax Withholding, Share-based Payment Arrangement	—	—	$510	$780
Proceeds from Issuance of Private Placement	—	$115,625	$0	$0
Payments for Repurchase of Private Placement	—	$7,485	$0	$0
Proceeds from Warrant Exercises	—	$69,375	$0	$0
Payments for Repurchase of Warrants	—	$1,734	$0	$0
Net Cash Provided by (Used in) Financing Activities	$25,042	$175,849	$14,587	$426,664
Increase (Decrease) in Other Receivables	$-1,783	$475	$0	$0
Increase (Decrease) in Prepaid Expense and Other Assets	$-447	$2,871	$2,588	$5,704
Increase (Decrease) in Accounts Payable	$-2,436	$-163	$-146	$981
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities	$-9,048	$-1,111	$6,662	$11,500

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("AVTX","financials")

Full statements spill as a table. For one cell: =jivedata("AVTX","Revenue") or =jivedata("AVTX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.